Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

KIFA has started collecting applications for IPOs

7/25/24 QIFA

M.Video CEO Bilan Uzhakhov acquired 53.63% of the company

7/25/24 MVID

ITC reported for 6 months of 2024 by RAS

7/24/24 WTCM

NCSP reports for 6 months of 2024 by RAS

7/24/24 NMTP

ZIL reported for 6 months of 2024 by RAS

7/24/24 ZILL

Krasny Oktyabr reported for 6 months of 2024 by RAS

7/24/24 KROT

Novatek reports for 6 months of 2024 by RAS

7/24/24 NVTK

NPF Tinkoff Pension is preparing to launch

7/24/24 T

Mosenergo increased electricity generation by 6.7%

7/24/24 MSNG

RusHydro's output grew by 7% in the 1st half of the year

7/24/24 HYDR